About us

Biomolix logo with a molecular diagram and the tagline 'Discover. Deliver.'

Biomolix is a scientific consulting partner focused on early-stage small-molecule drug discovery.  We work with biotech and pharma clients from target selection through lead optimization, applying deep experience and rigorous analysis to drive faster, better-informed decisions.

Discover early. Deliver faster.

Portrait of a woman with shoulder-length dark hair, smiling, wearing a black blazer and a necklace, against a blurred beige background.

Betty Chan, PhD

Principal Consultant and Founder

Betty is a seasoned drug discovery scientist with nearly 20 years of biotech experience and deep expertise in biochemistry, protein sciences, and lead discovery.  As Principal Consultant and Founder of Biomolix and co-founder of a biotech newco, Betty thrives on driving innovation and delivering results.

She has built and scaled R&D capabilities at early-stage biotech companies, successfully advancing programs from target validation through IND-enabling studies.  She led discovery efforts for AUTX-703, a first-in-class KAT2A/B degrader currently in Phase 1 clinical trials and played a key role in the discovery and characterization of H3B-8800, a clinical-stage SF3B1 modulator.  Her scientific contributions include 12 publications, 2 patents, and multiple conference presentations.

Betty earned her PhD in Biological Chemistry and Molecular Pharmacology from Harvard University.  She is currently a Forté Fellow pursuing a part-time MBA at UNC-Kenan Flagler Business School, complementing her scientific expertise with formal business training.